A three-chemical cocktail, distinct from complex gene therapies, has been shown to rejuvenate brain organoids and is being prepared for Phase 1 human trials. The treatment is designed to be taken as a simple oral pill, drastically increasing its potential accessibility and ease of use.

To pioneer treatments in the new field of aging, the company's strategy is to create new combinations from existing products with established human safety profiles. This adheres to a strict "do no harm" principle, significantly reducing the safety risk and regulatory uncertainty inherent in developing entirely new chemical entities for a preventative, long-term indication.

InflaRx's strategy targets the C5a pathway, implicated in many inflammatory conditions. By focusing on this single mechanism, their drug could potentially treat a wide range of diseases, from skin conditions to kidney disease, effectively creating a valuable "pipeline in a drug."

A partnership with Novartis focuses on drug targets at the intersection of exercise and aging. The goal is to create "exercise mimetics"—drugs that replicate the health benefits of physical activity. This novel approach frames a new therapeutic class complementary to "diet mimetics" like incretin drugs.

Inspired by the broad benefits of drugs like GLP-1s, Gordian is proactively creating "atlases" of target effects across multiple organs (heart, kidney, liver). This strategy positions them to discover the next class of drugs that treat multiple related conditions simultaneously, a key focus for their internal pipeline.

The company's strategy for its IL-23 inhibitor isn't just a single drug approval. They follow an established industry model where one successful drug becomes a pipeline for multiple related inflammatory indications like psoriasis, Crohn's, and ulcerative colitis, dramatically expanding its market potential over time.

The TL1A biological target is attracting massive investments, not just for its promise in IBD, but for its potential across numerous inflammatory conditions. With data expected in up to seven different diseases, investors see a Humira-like opportunity to develop a single molecule into a multi-billion dollar franchise, justifying huge valuations and deals.

Coya's therapeutic approach is not limited to ALS. The company views the underlying mechanism—dysfunctional regulatory T-cells driving neuroinflammation—as a common pathway in other conditions like frontotemporal dementia, Alzheimer's, and Parkinson's. This positions their drug as a platform technology, creating a broader pipeline and de-risking the company from reliance on a single indication.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.